Regensburg

• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host … Recruiting
  2025-521849-25-00 4 2026-02-17 Chronic Graft-Versus-Host Disease
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 5 2026-01-16 ​​IDH-mutant grade 2 or 3 astrocytoma​
• A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting
  2024-511508-18-00 9 2026-01-05 Chronic graft versus host disease.
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489 Recruiting
  2025-521155-23-00 4 2025-12-19 Pulmonary Arterial Hypertension
• Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis Recruiting
  2024-518288-37-00 3 2025-12-18 Lupus Nephritis
• ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha … Recruiting
  2025-522718-22-00 4 2025-12-16 Gastroesophageal Adenocarcinoma
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting
  2025-521644-37-00 4 2025-11-28 locally advanced or metastatic penile squamous cell carcinoma
• adIVO Recruiting
  2024-520219-42-00 10 2025-11-18 ivosidenib maintenance after SOC adjuvant chemotherapy in curative mID
• A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• Silexan® in mild to moderate major depressive disorder Recruiting
  2025-521744-37-00 5 2025-11-17 Mild to moderate major depressive disorder
• A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting
  2024-512849-17-00 5 2025-11-14 Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
• TYPER Recruiting
  2024-520290-12-00 6 2025-11-04 Hormone receptor–positive (HRpos)/human epidermal growth factor recept
• A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co … Recruiting
  2025-520690-39-00 4 2025-11-04 Moderately to Severely Active Ulcerative Colitis (UC)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel

Showing 49–72 of 295 trials